

## JNK-IN-8, JNK inhibitor

Catalog	Unit
TBI5186-5MG	5 mg
TBI5186-25MG	25 mg

### Product Details

**Formal Name:** 3-[[4-(Dimethylamino)-1-oxo-2-buten-1-yl]amino]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide

**Alternate Names:** JNK Inhibitor XVI

**Molecular Formula:** C<sub>29</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub>

**Formula Weight:** 507.6

**CAS Number:** 1410880-22-6


**Purity:** >98%

**Formulation:** Powder

**Solubility:** Soluble in DMSO (45 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years.



### Applications

JNK inhibitor

### Functions

Irreversible, specific JNK (c-Jun N-terminal Kinase) inhibitor (IC<sub>50</sub>s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3) that forms a covalent bond with a conserved cysteine in the ATP-binding site. Suppresses triple-negative breast cancer (TNBC) cell growth in vitro and in vivo through upregulation of lysosome biogenesis and autophagy. Suppresses inflammation and oxidative stress during LPS-induced acute lung injury in mice. Alleviates cognitive impairment, neuroinflammation, and NLRP3 inflammasome activation in a rat model of acute respiratory distress syndrome (ARDS).

### Application Procedures

First dissolved in DMSO (45 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

**For research use only.**